Related Experiment Video

Updated: Jul 5, 2025

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

19.5K

Role of Probiotics in the Treatment and Prevention of Common Gastrointestinal Conditions in Children

Iva Hojsak1,2,3, Sanja Kolaček1,2

  • 1Department of Pediatrics, Referral Center for Pediatric Gastroenterology and Nutrition, Children's Hospital, Zagreb, Croatia.

Pediatric Gastroenterology, Hepatology & Nutrition
|January 22, 2024
PubMed

Insights

This review examines probiotic use for pediatric gastrointestinal diseases. It highlights the need for strain-specific recommendations regarding dose and duration for effective treatment and prevention.

Area of Science:

  • Microbiology
  • Pediatric Gastroenterology
  • Nutritional Science

Background:

  • Probiotics, live microorganisms, offer health benefits when consumed adequately.
  • Current guidelines often lack strain-specific recommendations for probiotics, hindering clinical application.
  • Healthcare professionals need clear guidance on probiotic selection, dosage, and duration for specific pediatric conditions.

Purpose of the Study:

  • To review evidence on probiotic use in preventing and treating common pediatric gastrointestinal diseases.
  • To analyze the impact of specific probiotic strains and dosages.
  • To summarize data on potential side effects and product quality.

Main Methods:

  • Narrative review of existing scientific literature.
  • Focus on studies detailing probiotic strains, dosages, and clinical outcomes.
  • Inclusion of data on safety and product quality.

Main Results:

  • Evidence for probiotic efficacy varies significantly by strain and condition.
  • Lack of standardized recommendations complicates clinical practice.
  • Information on side effects and product quality is often limited.

Conclusions:

  • Strain-specific recommendations are crucial for effective probiotic therapy in children.
  • Further research is needed to establish clear guidelines for pediatric gastrointestinal disorders.
  • Quality control and transparent labeling of probiotic products are essential.

Keywords:
Antibiotic-associatedGastroenteritisHelicobacter pyloriIrritable bowel syndromeLacticaseibacillusLactobacillusLimosilactobacillusSaccharomyces

More Related Videos

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods08:38

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods

Published on: September 10, 2016

24.5K
Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay09:20

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

12.6K

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
410
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
120
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
94
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
430